Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab + surufatinib + EP/EC first-line study in extensive-stage small cell lung cancer
ChiCTR2400085032Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- May 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of serplulimab, surufatinib, etoposide, cisplatin and carboplatin in small cell lung cancer (SCLC), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoints: progression-free survival and safety. Planned start May 2024; status: not yet recruiting.
02
Drugs
serplulimabsurufatinibetoposidecisplatincarboplatin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2400085032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085032.